Engineered human stomach organoids, transplanted into mice, produced insulin-secreting cells, offering a potential new ...

Abzena and Mabqi bring together two organizations that are focused on advancing antibody innovation through integration.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

Researchers analyzed the role of NUDT5 and its interaction with other proteins in the folate pathway and in regulating purine synthesis.

The data shows that downregulating PU.1 promotes the expression of immunoregulatory proteins on microglia that help protect cognitive function.

CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation.

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

The goal of the project is to develop novel approaches that strengthen and reduce the costs of domestic mAb biomanufacturing to protect against and treat infection by filoviruses.

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.

A novel 3D-printed nanofiltration module delivers nearly double the saccharide recovery rate and lowers costs.

Small biotechs are encouraged to develop robust processes early to avoid wasted time and increased costs on repeating scale-up.